Regeneron is entering radiopharmaceuticals through a collaboration with Telix to co-develop and co-commercialize next-generation radiopharmaceutical therapies and related diagnostics. The partnership is structured on a 50/50 cost- and profit-sharing model, with Telix receiving an initial upfront payment for four programs and options to add additional targets. The agreement pairs Regeneron’s antibody discovery capabilities, including VelocImmune, with Telix’s radiopharmaceutical development, manufacturing, and global supply chain infrastructure. Both companies also plan to develop radio-diagnostics to support patient selection and treatment response assessment across solid tumor targets.